# 胰高血糖素市场 > 胰高血糖素市场研究报告按适应症（低血糖、糖尿病酮症酸中毒、其他适应症）、给药途径（静脉注射、皮下、肌肉注射）、胰高血糖素来源（人源、合成、动物来源）、剂型（注射剂、鼻用喷雾剂、其他剂型）及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.72% - **2024:** $ 9.01 Billion - **2025:** $ 9.61 Billion - **2035:** $ 18.42 Billion - **Key Players:** Novo Nordisk (DK), Sanofi (FR), Eli Lilly and Company (US), Boehringer Ingelheim (DE), Amgen(US), Pfizer (US), Bristol-Myers Squibb (US), Mylan (US) **Report ID:** MRFR/HC/28295-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/glucagon-market-30032 --- ## Market Summary ## **Glucagon Market Overview** As per MRFR analysis, the Glucagon Market Size was estimated at 9.01 (USD Billion) in 2024. The Glucagon Market Industry is expected to grow from 9.61 (USD Billion) in 2025 to 17.26 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.72% during the forecast period (2025 - 2034). ### **Key Glucagon Market Trends Highlighted** Key market drivers for glucagon include the increasing prevalence of diabetes, rising demand for diabetes management, and technological advancements in glucagon delivery devices. Opportunities lie in expanding into emerging markets, developing combination therapies, and leveraging personalized medicine approaches. Recent trends in the glucagon market include the emergence of biosimilar glucagon, the development of long-acting glucagon formulations, and the growing adoption of telemedicine for diabetes management. Technological advancements, such as continuous glucose monitoring devices and automated glucagon delivery systems, are transforming the market by improving patient safety and convenience. To capture these opportunities and address market demands, players are focusing on innovation and collaboration. Companies are investing in research and development to bring new products and therapies to market while also partnering with healthcare providers and patient advocacy groups to improve patient outcomes and access to care. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Glucagon Market Drivers** ### **Technological Advancements Drive Innovation in the Glucagon Market** There are a number of important drivers for the significant growth of the Glucagon Market in the coming years. First of all, the increasing prevalence of diabetes is one of the most important driving factors, as it is a major risk factor for developing glucagon deficiency. According to the International Diabetes Federation, in 2019, there were an estimated 463 million adults (20-79 years) living with diabetes, and the number is expected to rise to 700 million by 2045. Ultimately, as the number of people with diabetes will be increasing, the demand for glucagon will also increase as people with diabetes are the primary consumers of this drug since it is currently used for the treatment of severe hypoglycemia. Another important factor is the increasing adoption of new and innovative technologies. Recently, several new technologies have been developed to deliver glucagon, making it easier and more convenient for patients to consume it. For example, in 2019, Eli Lilly and Company launched the first-ever pre-filled glucagon pen, which is more user-friendly and less intimidating than a traditional glucagon injection kit. These technologies continue to develop, and it is expected that the increasing innovation in the ways glucagon can be delivered to patients will continue to drive growth in the global glucagon market. Finally, the increasing awareness of glucagon deficiency can be considered another driving factor. Previously, glucagon deficiency was often misdiagnosed or not diagnose at all. However, today, it is becoming increasingly more diagnosed and recognized, largely thanks to efforts of patient advocacy groups and healthcare professionals, who work towards raising awareness about this condition. Overall, there are a number of important drivers for the significant growth of the Glucagon Market in the coming years, such as the increasing prevalence of diabetes, the increasing adoption of innovative new technologies, and the increasing awareness of glucagon deficiency. ### **Rising Prevalence of Diabetes Contributes to Glucagon Market Expansion** The Glucagon Market is primarily driven by the increasing incidence of diabetes. Diabetes is a chronic disease that affects the body's ability to produce and use insulin. Insulin is a hormone that helps glucose get from the blood into the body’s cells. When people are living with diabetes, the body does not make enough insulin, or it cannot use its own insulin as well as it should. People with diabetes, therefore, may have too much sugar in their blood and thus suffer from a variety of complications, such as glucagon deficiency. Glucagon is a hormone produced by the pancreas. It raises blood glucose levels by stimulating the liver to release glucose. Glucagon deficiency may occur in people with diabetes when the pancreas fails to produce enough glucagon or when the body fails to respond to glucagon properly. This results in severe hypoglycemia, which can lead to loss of consciousness and might eventually lead to death. Diabetes prevalence is expected to grow in the coming years. This is due to an array of reasons, such as the growing obesity and inactivity rates. As such, up to an additional 160 million people worldwide will have diabetes by 2045. This is likely to propel the demand for glucagon in the coming future, thus driving the Glucagon Market to rise. ### **Advancements in Glucagon Delivery Devices Enhance Patient Convenience** During the last several years, there have been a lot of advances in the development of glucagon delivery devices. It means that it now has become much easier and more convenient for patients to actually use glucagon. It is likely to drive the growth of the Glucagon Market in a few years. Previously, glucagon delivery devices were bulky and hard to use. In an emergency situation, such as severe hypoglycemia, it was very challenging to apply for patients. However, currently, newer glucagon delivery devices have a friendlier and easier design, so they no longer have to be intimidating. For instance, in 2019, Eli Lilly and Company introduced the first-ever pre-filled glucagon pen. It is supposed to be much easier to use and much less intimidating than traditional glucagon injection kits. In the following years, there are supposed to be even more advances in the development of glucagon-delivery devices. It means that it would become even easier and more convenient for patients to actually use glucagon and drive the growth of the global glucagon market. ## **Glucagon Market Segment Insights** ### **Glucagon Market Indication Insights** The Glucagon Market is segmented by Indication into Hypoglycemia, Diabetic Ketoacidosis, and Other Indications. The Hypoglycemia segment held the largest market share in 2023 and is projected to continue to dominate the market throughout the forecast period. The growth of this segment can be attributed to the increasing prevalence of diabetes and the rising demand for effective treatments for hypoglycemia. The Diabetic Ketoacidosis segment is also expected to witness significant growth over the forecast period, owing to the increasing incidence of diabetes and the growing awareness about the importance of early treatment for DKA. The Other Indications segment includes conditions such as hyperkalemia and glycogen storage diseases, and is expected to grow at a steady pace during the forecast period. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Glucagon Market Route of Administration Insights** The Glucagon Market segmentation by Route of Administration comprises Intravenous, Subcutaneous, and Intramuscular. Intravenous administration dominated the market with a revenue share of over 70% in 2023 and this trend is projected to continue throughout the forecast period. This dominance can be attributed to the need for immediate hormone delivery, precision dosing, and faster onset of action compared to other routes of administration. The ease of administration and reduced risk of infection associated with IV administration further contribute to its widespread adoption. Subcutaneous administration is expected to witness significant growth over the forecast period, driven by the development of sustained-release formulations and wearable devices. Intramuscular administration, while less common, is preferred in emergency situations and for patients who cannot tolerate oral or IV administration. ### **Glucagon Market Glucagon Origin Insights** The Glucagon Origin segment plays a vital role in the Global Glucagon Market, influencing market growth and dynamics. In 2023, the Human origin segment held a dominant market share, accounting for approximately 58% of the Glucagon Market revenue. This dominance is attributed to the high efficacy and safety profile of human glucagon products, which are derived from purified human pancreas. Synthetic glucagon, which is produced through chemical synthesis, is expected to experience a significant rise in demand during the forecast period, owing to its cost-effectiveness and reduced risk of contamination compared to animal-derived glucagon. Animal-derived glucagon, obtained from animal pancreas, is anticipated to witness a gradual decline in market share due to concerns regarding potential immune reactions and disease transmission. Overall, the Glucagon Origin segment offers valuable insights into the market dynamics, enabling stakeholders to make informed decisions. The growing demand for human and synthetic glucagon products is expected to drive the overall Glucagon Market growth in the coming years. ### **Glucagon Market Dosage Form Insight ** The Glucagon Market is segmented by dosage form into injectable, nasal spray, and other dosage forms. The injectable segment held the largest market share in 2023, and it is expected to continue to dominate the market throughout the forecast period. The growth of the injectable segment can be attributed to the increasing prevalence of diabetes and the rising demand for injectable therapies. The nasal spray segment is expected to witness significant growth over the forecast period due to its ease of administration and convenience. Other dosage forms, such as oral and transdermal, are also expected to contribute to the growth of the overall market. ### **Glucagon Market Regional Insights** The regional analysis of the Glucagon Market offers insights into the market's performance across different regions, including North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. The region's well-established healthcare infrastructure, high prevalence of diabetes, and increasing adoption of advanced therapies contribute to its substantial market size. Europe follows North America in terms of market share, driven by a large patient population, favorable reimbursement policies, and the presence of leading pharmaceutical companies. APAC is projected to exhibit the highest growth rate during the forecast period, owing to the rising prevalence of diabetes and increasing healthcare expenditure in emerging economies like China and India. South America and MEA are expected to contribute modest shares to the global Glucagon Market, with MEA showing potential for growth due to expanding healthcare access and increasing awareness about diabetes management. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Glucagon Market Key Players and Competitive Insights** Major competitors in the Glucagon Market industry are constantly working on strengthening their positions and increasing their market share. The leading Glucagon Market players are involved in active research and development to offer new innovative products and therapies that will meet the changing needs of patients. Partnerships, cooperation, and acquisitions are actively taking place in the liquid propane industry as companies are focused on strengthening their positions in crucial markets. The Glucagon Market growth is conditioned by various government and industry-led factors belonging to the market environment that work on its development and influence the market growth and development. Regarding the dynamics of competition, it is important to note that new players are constantly entering the market, and the existing companies are either acquiring new partners or expanding. Novo Nordisk is one of the leading companies in the global healthcare sector, occupying a strong position in the Glucagon Market industry. The company is highly praised for its extensive experience and innovations, which helped Novo Nordisk develop a powerful portfolio of first-class Glucagon products. The product is known for its quality, efficacy, safety, and high ease of use, which are critical factors influencing the company’s leading position on the market. Ongoing research and development and global outreach have significantly strengthened the company's position in Glucagon Market. Eli Lilly and Company is another important player in the Glucagon Market that has contributed to the product's development and commercialization. The company’s Glucagon products are of great quality and reliability and are highly suited for use. Eli Lilly and Company actively invests in research and development to expand the product portfolio and meet the emerging needs. Ease of administration and focus on patient care helps the company to hold a strong market position. ### **Key Companies in the Glucagon Market Include** ### **Glucagon Industry Developments** The rising prevalence of diabetes, increasing demand for injectable glucagon, and growing adoption of continuous glucose monitoring (CGM) systems are primarily driving market growth. Key industry developments include the launch of new products, such as Eli Lilly's Baqsimi nasal glucagon, and strategic collaborations between market players to expand their product portfolios. The market is also witnessing increasing investments in research and development of novel glucagon-based therapies, with a focus on non-injectable formulations and combination therapies. ## **Glucagon Market Segmentation Insights** ### **Glucagon Market Indication Outlook** ### **Glucagon Market Route of Administration Outlook** ### **Glucagon Market Glucagon Origin Outlook** ### **Glucagon Market Dosage Form Outlook** ### **Glucagon Market Regional Outlook** ## Market Drivers ### 老年糖尿病人口增长 老年人口的增加是胰高血糖素市场的重要驱动力。老年人更容易患上糖尿病及其并发症，包括低血糖。随着全球人口的老龄化，对胰高血糖素产品的需求可能会相应增加。这一人口结构的变化需要量身定制的医疗解决方案，包括胰高血糖素，以有效管理老年患者的糖尿病。市场分析师预测，老年人群体将对胰高血糖素市场的整体增长做出重要贡献，因为医疗系统正在适应这一人群的独特需求。因此，胰高血糖素市场有望扩张，推动力在于为老龄化人口提供有效的糖尿病管理解决方案的迫切需求。 ### 糖尿病的发病率不断增加 糖尿病，特别是1型和2型糖尿病的发病率上升，是促使胰高血糖素市场增长的主要驱动力。根据最近的统计数据，糖尿病患者的数量持续增加，导致对有效管理解决方案的需求加大。胰高血糖素市场作为对抗严重低血糖的关键激素，在糖尿病护理中发挥着重要作用。预计胰高血糖素产品市场将显著扩展，估计在未来几年内复合年增长率（CAGR）将超过10%。这一趋势表明胰高血糖素市场将呈现强劲的增长轨迹，因为医疗服务提供者越来越认识到胰高血糖素在糖尿病管理中的必要性。 ### 对低血糖的认识和教育提升 对低血糖及其管理的教育日益受到重视，这对胰高血糖素市场产生了积极影响。医疗服务提供者越来越关注对患者和护理人员进行培训，强调在紧急情况下胰高血糖素的重要性。这种意识的提高可能会导致胰高血糖素产品的处方和使用量增加。包括研讨会和在线资源在内的教育举措正在实施，以告知患者如何识别低血糖症状以及胰高血糖素的适当使用。随着意识的不断提高，胰高血糖素市场预计将受益于需求的激增，因为越来越多的人希望为潜在的低血糖事件做好准备。 ### 胰高血糖素产品的监管支持 监管机构在通过支持性政策和指导方针塑造胰高血糖素市场方面发挥着至关重要的作用。最近新胰高血糖素配方和给药方法的批准为市场参与的增加铺平了道路。监管机构还鼓励该领域的研究与开发，这可能导致新型胰高血糖素疗法的推出。良好的监管环境可能会刺激制造商之间的竞争，从而使消费者能够获得更广泛的胰高血糖素产品。这一动态预计将增强胰高血糖素市场的整体增长，因为公司努力满足患者和医疗服务提供者不断变化的需求。 ### 胰高血糖素输送中的技术创新 药物输送系统的进步正在改变胰高血糖素市场。预填充注射器和自动注射器等创新正在提高胰高血糖素产品的使用便利性和可及性。这些技术不仅改善了患者的依从性，还确保在低血糖发作期间及时给药。用户友好设备的引入可能会吸引更广泛的患者群体，从而扩大市场覆盖范围。此外，智能技术的整合，例如提醒用户携带胰高血糖素的移动应用程序，预计将促进市场发展。随着这些创新的普及，胰高血糖素市场预计将见证显著增长，推动因素是患者和医疗专业人员的采用率提高。 ## Future Outlook 胰高血糖素市场预计将在2024年至2035年间以6.72%的年复合增长率增长，推动因素包括糖尿病患病率上升、技术进步以及对低血糖管理的认识提高。 **New opportunities:** - 为学校和工作场所开发用于紧急情况的胰高血糖素自动注射器。 到2035年，胰高血糖素市场预计将实现显著增长，反映出不断变化的医疗保健需求。 ## Segment Insights ### 按适应症：低血糖（最大）与糖尿病酮症酸中毒（增长最快） 在胰高血糖素市场中，适应症细分市场主要由低血糖症主导，其市场份额最大，因为它在胰岛素过量患者的紧急情况下得到了广泛应用。该细分市场正在发展，反映出医疗专业人员和公众对在低血糖发作中迅速干预重要性的日益认识。相比之下，糖尿病酮症酸中毒虽然规模较小，但由于1型糖尿病的发病率不断上升以及胰高血糖素在急救环境中作为关键干预措施的有效性，成为增长最快的细分市场。 适应症细分市场的增长趋势主要受到全球糖尿病发病率上升的推动，这使得在不同情况下需要使用胰高血糖素。此外，针对糖尿病危机的更好紧急响应的推动，加上胰高血糖素配方的进步，正在催化糖尿病酮症酸中毒作为市场增长的关键领域。此外，患者对胰高血糖素在管理严重低血糖和糖尿病紧急情况中的作用的认识不断提高，进一步推动了该细分市场的市场动态。 低血糖（显性）与糖尿病酮症酸中毒（新兴） 低血糖被认为是胰高血糖素市场的主要指示，因其在紧急情况下对治疗的关键和迫切需求而显著。经历低血糖水平的患者需要迅速干预，而胰高血糖素在逆转这种情况中的作用不可或缺。这一必要性强调了低血糖管理的既定框架，将胰高血糖素嵌入护理协议中，并推动稳定的需求。另一方面，虽然糖尿病酮症酸中毒正在新兴，但随着糖尿病病例的增加，其相关性日益增强。及时给予胰高血糖素可以挽救处于糖尿病危机中的患者的生命，促进医疗从业者的意识并推动市场的采用。随着胰高血糖素制剂的演变，糖尿病酮症酸中毒的市场地位预计将得到加强，吸引更多的投资和研究进入这一领域。 ### 按给药途径：皮下（最大）与静脉注射（增长最快） 在胰高血糖素市场中，按给药途径划分的市场份额显示，皮下注射目前主导市场，这主要归因于其使用方便和患者依从性。静脉给药虽然不太普遍，但由于其快速起效，尤其在紧急情况下越来越受到欢迎。随着市场的发展，这些方法的采用程度因临床疗效和患者偏好而有所不同。 给药方法：皮下（主导）与静脉（新兴） 皮下给药的胰高血糖素被认为是主要的给药途径，主要由于其简单性和微创性，使其成为糖尿病患者在家使用的首选方案。这种方法有利于自我给药，提高患者的依从性，从而增强其在市场上的强大地位。另一方面，静脉给药正在迅速兴起，特别是在医院环境中，因为它在急性低血糖事件中提供了立即的治疗效果。尽管需要经过培训的医疗专业人员进行给药，但其吸引力在于能够在危重护理场景中迅速提高血糖水平。 ### 通过胰高血糖素市场来源：人类（最大）与合成（增长最快） 在胰高血糖素市场中，人源胰高血糖素目前是最大的细分市场，因为它被广泛接受并且具有成熟的治疗用途。它占据了显著的市场份额，因为它主要用于紧急治疗，并因其安全性和有效性而受到认可。合成胰高血糖素细分市场虽然相对较小，但由于生物技术的进步和制药公司日益增长的兴趣，正在迅速获得关注。该细分市场满足了对提供特定优势的替代品在剂量和给药方面日益增长的需求。 胰高血糖素市场起源：人类（主导）与合成（新兴） 人胰高血糖素因其在市场上的历史存在而受到认可，主要来源于人类蛋白质，使其成为治疗应用中的主导者。它在紧急医疗协议中的良好记录，特别是在严重低血糖方面，增强了其在临床环境中的价值。相比之下，合成胰高血糖素代表了一个新兴领域，其特点是实验室生产。这一创新使得质量更加一致，并且有潜力采用新型给药方法，这在不断发展的糖尿病管理领域中尤为吸引人。对便捷给药的日益需求推动了对合成制剂的兴趣。 ### 按剂型：注射剂（最大）与鼻用喷雾剂（增长最快） 在胰高血糖素市场中，注射剂型占据了重要份额，是医疗专业人员最广泛使用和信任的剂型。该细分市场受益于既定的协议和广泛的熟悉度，确保了强劲的市场渗透。相反，尽管鼻用喷雾剂的市场份额较小，但由于其用户友好的给药方式和快速的起效时间，正受到患者和医疗提供者的关注。 剂型细分市场的增长趋势受到糖尿病和低血糖发病率增加的推动，迫切需要满足患者偏好的创新解决方案。注射剂型凭借其可靠的疗效巩固了其地位，而鼻用喷雾剂则迅速崛起，得益于配方技术的进步以及通过减少与针头相关的焦虑来提高患者依从性的关注。 注射剂（主流）与鼻用喷雾剂（新兴） 注射剂型是胰高血糖素市场的主导产品，其特点是使用模式成熟且得到临床医生的支持。这种剂型已成为可靠性和有效性的代名词，巩固了其在治疗严重低血糖事件中的首选地位。另一方面，鼻用喷雾剂作为一种可行的替代方案正在崭露头角，旨在减少患者的恐惧感，特别是对于那些在注射时感到焦虑的患者。鼻用喷雾剂的给药方便性和快速吸收特性使其成为一个有吸引力的选择，吸引了更广泛的患者群体。随着这两种剂型的共存，市场正在经历由以患者为中心的创新和优化治疗结果的追求所驱动的动态演变。 ## Regional Market Share Analysis ### 北美：胰高血糖素市场的领导者 北美是胰高血糖素最大的市场，占全球份额的约45%。该地区的增长受到糖尿病患病率上升、胰高血糖素配方的进步以及支持性监管框架的推动。美国在这一市场中处于领先地位，其次是加拿大，后者占有约15%的市场份额。新胰高血糖素产品的监管批准进一步促进了市场扩展，提高了患者的可及性和负担能力。 北美的竞争格局强劲，主要参与者包括礼来、诺和诺德和赛诺菲。这些公司积极参与创新和战略合作，以增强其产品供应。先进的医疗基础设施和对糖尿病管理的高度意识使该地区的市场地位强劲。以患者为中心的解决方案的关注预计将在未来几年推动进一步增长。 ### 欧洲：新兴市场动态 欧洲的胰高血糖素市场正在经历显著增长，占全球份额的约30%。糖尿病发病率的上升和对有效治疗选择的需求增加是主要驱动因素。德国和法国是该地区最大的市场，分别占市场份额的约10%和8%。旨在改善糖尿病护理的监管举措也在促进市场扩展，推动创新和可及性。 欧洲的主要国家包括德国、法国和英国，主要参与者如赛诺菲和勃林格殷格翰主导着市场。竞争环境的特点是成熟公司与新兴初创企业的混合，后者专注于新型胰高血糖素配方。欧洲药品管理局（EMA）在监管和批准新疗法方面继续发挥关键作用，确保患者的安全性和有效性。这种监管支持对维持市场增长至关重要。 ### 亚太地区：快速增长的市场 亚太地区正在迅速崛起为胰高血糖素市场的重要参与者，目前占全球份额的约20%。增长主要受到糖尿病发病率上升、医疗支出增加以及政府旨在改善糖尿病管理的举措的推动。中国和印度是领先市场，分别对整体市场份额贡献约10%和5%。该地区的监管机构越来越关注简化新胰高血糖素产品的批准流程，提高市场准入。 在亚太地区，竞争格局正在演变，跨国公司和本地企业都在争夺市场份额。礼来和安进等关键公司正在积极投资于研发，以推出创新的胰高血糖素解决方案。对糖尿病管理的日益关注和对有效治疗选择的需求预计将推动该地区的进一步增长，使其成为未来投资的重点。 ### 中东和非洲：新兴机会在前 中东和非洲（MEA）地区在胰高血糖素市场中逐渐崭露头角，目前占全球份额的约5%。增长受到糖尿病发病率上升和对医疗基础设施发展的日益关注的推动。南非和阿联酋等国在市场中处于领先地位，合计占有约3%的市场份额。该地区的监管机构开始实施旨在改善糖尿病治疗可及性的政策，预计将在未来几年促进市场增长。 MEA的竞争格局由本地和国际参与者的混合构成。美林和辉瑞等公司正在该地区建立存在，专注于提供负担得起的胰高血糖素解决方案。对糖尿病管理的日益关注和对有效治疗的需求正在推动市场需求。随着医疗系统的发展，MEA地区在胰高血糖素市场中呈现出显著的增长机会，吸引投资和创新。 ## Competitive Benchmarking 在胰高血糖素市场行业中，主要竞争对手不断努力巩固其地位并增加市场份额。领先的胰高血糖素市场参与者积极从事研究和开发，以提供新的创新产品和疗法，以满足患者不断变化的需求。 在液化石油气行业，合作、合作和收购活动正在积极进行，因为公司专注于在关键市场中巩固其地位。胰高血糖素市场的增长受到各种政府和行业主导因素的影响，这些因素属于市场环境，影响其发展并影响市场的增长和发展。 关于竞争动态，值得注意的是，新参与者不断进入市场，而现有公司要么收购新合作伙伴，要么扩展。 诺和诺德是全球医疗保健行业的领先公司之一，在胰高血糖素市场行业中占据强势地位。 该公司因其丰富的经验和创新而备受赞誉，这帮助诺和诺德开发出强大的优质胰高血糖素市场产品组合。该产品以其质量、疗效、安全性和高易用性而闻名，这些都是影响公司在市场上领先地位的关键因素。 持续的研究和开发以及全球拓展显著增强了公司在胰高血糖素市场中的地位。礼来公司是胰高血糖素市场的另一个重要参与者，为该产品的发展和商业化做出了贡献。 该公司的胰高血糖素市场产品质量高、可靠性强，非常适合使用。礼来公司积极投资于研究和开发，以扩展产品组合并满足新兴需求。便于管理和关注患者护理帮助公司保持强大的市场地位。 ## Recent News & Developments 糖尿病的日益普遍、对注射性胰高血糖素的需求增加以及持续血糖监测（CGM）系统的日益普及主要推动了市场增长。 行业的主要发展包括新产品的推出，例如礼来公司的Baqsimi鼻用胰高血糖素，以及市场参与者之间的战略合作，以扩展其产品组合。市场还见证了对新型胰高血糖素治疗的研究与开发的投资增加，重点是非注射剂型和联合治疗。 ## Report Scope | 2024年市场规模 | 9.007（十亿美元） | | --- | --- | | 2025年市场规模 | 9.612（十亿美元） | | 2035年市场规模 | 18.42（十亿美元） | | 复合年增长率（CAGR） | 6.72%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 胰高血糖素输送系统的进步提高了糖尿病管理中的患者依从性和治疗效果。 | | 主要市场动态 | 对胰高血糖素在糖尿病管理中需求的上升推动了制药公司之间的创新和竞争动态。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，胰高血糖素市场的预计市场估值是多少？** A: 到2035年，胰高血糖素市场预计将达到184.2亿美元的估值。 **Q: 2024年胰高血糖素市场的市场估值是多少？** A: 2024年，胰高血糖素市场的价值为90.07亿美元。 **Q: 在2025年至2035年的预测期内，胰高血糖素市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，胰高血糖素市场的预期年复合增长率（CAGR）为6.72%。 **Q: 在胰高血糖素市场中，哪些公司被视为关键参与者？** A: 在胰高血糖素市场的主要参与者包括诺和诺德、赛诺菲、礼来公司、博瑞医药、安进、辉瑞、百时美施贵宝和迈兰。 **Q: 到2035年，低血糖细分市场的预计值是多少？** A: 低血糖细分市场预计到2035年将达到75亿美元的价值。 **Q: 静脉给药在胰高血糖素市场中的表现如何？** A: 到2035年，静脉给药途径预计将增长到50亿美元的价值。 **Q: 到2035年，合成胰高血糖素的市场预期表现如何？** A: 合成胰高血糖素预计到2035年将达到60亿美元的市场价值。 **Q: 到2035年，预计哪种剂型将在胰高血糖素市场中占主导地位？** A: 预计注射剂型将在市场中占主导地位，到2035年将达到115亿美元。 **Q: 到2035年，糖尿病酮症酸中毒细分市场的预计市场价值是多少？** A: 糖尿病酮症酸中毒部分预计到2035年将达到55亿美元的价值。 **Q: 哪些趋势正在影响胰高血糖素市场的增长？** A: 胰高血糖素市场的增长受到糖尿病发病率增加和胰高血糖素配方进步的影响。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/glucagon-market-30032*